Preliminary single agent activity of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
暂无分享,去创建一个
A. Oza | M. Birrer | R. Perez | Yinghui Zhou | R. Ruiz-Soto | D. O’Malley | T. Bauer | W. Jeong | Jose F. Ponte | S. Seward | K. Moore | M. Kirby | Lainie P Martin | M. Michenzie